Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8

BMC Cancer

Volumn 6, Issue , 2006, Pages

  De Bortoli, Massimiliano ^a   Castellino, Robert C ^a   Lu, Xin Yan ^a   Deyo, Jeffrey ^b   Sturla, Lisa Marie ^c   Adesina, Adekunle M ^a   Perlaky, Laszlo ^a   Pomeroy, Scott L ^d   Lau, Ching C ^a   Man, Tsz Kwong ^a   Rao, Pulivarthi H ^a   Kim, John Y H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b St Jude Children's Research Hospital Baton Rouge   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; INITIATION FACTOR 1; INITIATION FACTOR 1D; LOMUSTINE; PROTEIN L30; PROTEIN S20; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHROMOSOME 10Q; CHROMOSOME 12P; CHROMOSOME 16Q; CHROMOSOME 17; CHROMOSOME 2P; CHROMOSOME 2Q; CHROMOSOME 7Q; CHROMOSOME 8; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DNA MICROARRAY; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; OVERALL SURVIVAL;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 8; GENE AMPLIFICATION; GENE DOSAGE; GENES, MYC; GENES, NEOPLASM; HUMANS; INFANT; MEDULLOBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE ELONGATION FACTOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS; SURVIVAL ANALYSIS;

EID: 33749402944     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-223     Document Type: Article

References (37)

1. Strother DR, Pollack IF, Fisher PG, Hunter JV, Woo SY, Pomeroy SL, Rorke LB: Tumors of the Central Nervous System. Principles and Practice of Pediatric Oncology 42003:778-785.
2. Ellison D: Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002, 28:257-282.
3. Giangaspero F, Bigner SH, Giordana MT, Kleihues P, Trojanowski JQ: Medulloblastoma. Pathology and genetics: Tumours of the Nervous System. World Health Organization Classification of Tumors 2000:96-103.
4. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL: Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004, 22:994-998.
5. Gilbertson RJ, Gajjar A: Molecular biology of medulloblastoma: will it ever make a difference to clinical management? J Neurooncol 2005, 75:273-278.
6. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherlee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415:436-442.
7. Bayani J, Zielenska M, Marrano P, Kwan NY, Taylor MD, Jay V, Rutka JT, Squire JA: Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 2000, 93:437-448.
8. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS, Strother DR, Burger PC: Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002, 94:552-560.
9. Biegel JA: Cytogenetics and molecular genetics of childhood brain tumors. Neuro-oncol 1999, 1:139-151.
10. Pan E, Pellarin M, Holmes E, Smirnov I, Misra A, Eberhart CG, Burger PC, Biegel JA, Feuerstein BG: Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 2005, 11:4733-4740.
11. Gilhuis HJ, Anderl KL, Boerman RH, Jeuken JM, James CD, Raffel C, Scheithauer BW, Jenkins RB: Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature. Clin Neurol Neurosurg 2000, 102:203-209.
12. Tong CY, Hui AB, Yin XL, Pang JC, Zhu XL, Poon WS, Ng HK: Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg 2004, 100:187-193.
13. Blaney SM, Boyett J, Friedman H, Gajjar A, Geyer R, Horowtiz M, Hunt D, Kierari M, Kun L, Packer R, Phillips P, Pollack IF, Prados M, Heideman R: Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol 2005, 23:525-531.
14. Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, Sanford RA, Mulhern RK, James HE, Freeman CR, Seidel FG, Kun LE: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993, 328:1725-1731.
15. Packer RJ, Rood BR, Macdonald TJ: Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003, 39:60-67.
16. Thomas PR, Deutsch M, Kepner JL, Boyett JM, Krischer J, Aronin P, Albright L, Allen JC, Packer RJ, Linggood R, Mulhern R, Stehbens JA, Langston J, Stanley P, Duffner P, Rorke L, Cherlow J, Friedman HS, Finlay JL, Vietti TJ, Kun LE: Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000, 18:3004-3011.
17. Strother D, Ashley D, Kellie SJ, Patel A, Jones-Wallace D, Thompson S, Heideman R, Benaim E, Krance R, Bowman L, Gajjar A: Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001, 19:2696-2704.
18. Sambrook J, Russell DW: Molecular Cloning, a Laboratory Manual. New York 2001:6.7-6.11; 6.27.
19. Kim JY, Sutton ME, Lu DJ, Cho TA, Goumnerova LC, Goritchenko L, Kaufman JR, Lam KK, Billet AL, Tarbell NJ, Wu J, Allen JC, Stiles CD, Segal RA, Pomeroy SL: Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999, 59:711-719.
20. Rao PH: Comparative genomic hybridization for analysis of changes in DNA copy number in multiple myeloma. Methods. Mol Med 2005, 113:71-83.
21. Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001, 98:31-36.
22. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
23. Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, Terry PA, Freitas JR, Boag JM, Cummings AJ, Kees UR: Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR - how well do they correlate? BMC Genomics 2005, 6:59.
24. Batra SK, McLendon RE, Koo JS, Castelino-Prabhu S, Fuchs HE, Krischer JP, Friedman HS, Bigner DD, Bigner SH: Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995, 24:39-45.
25. Cogen PH, McDonald JD: Tumor suppressor genes and medulloblastoma. J Neurooncol 1996, 29:103-112.
26. Gilbertson R, Wickramasinghe C, Hernan R. Balaji V, Hunt D, Jones-Wallace D, Crolla J, Perry R, Lunec J, Pearson A, Ellison D: Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001, 85:705-712.
27. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW: Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004, 10:5482-5493.
28. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifenberger G, Korshunov A, Lichter P: Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005, 23:8853-8862.
29. Biegel JA, Janss AJ, Raffel C, Sutton L, Rorke LB, Harper JM, Phillips PC: Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res 1997, 3:473-478.
30. Emadian SM, McDonald JD, Gerken SC, Fults D: Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res 1996, 2:1559-1564.
31. Jung HL, Wang KC, Kim SK, Sung KW, Koo HH, Shin HY, Ahn HS, Shin HJ, Cho BK: Loss of heterozygosity analysis of chromosome 17p13.1-13.3 and its correlation with clinical outcome in medulloblastomas. J Neurooncol 2004, 67:41-46.
32. Nicholson J, Wickramasinghe C, Ross F, Crolla J, Ellison D: Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation. Mol Pathol 2000, 53:313-319.
33. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC: Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004, 63:441-449.
34. Joseph P, O'Kernick CM, Othumpangat S, Lei YX, Yuan BZ, Ong TM: Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol Carcinog 2004, 40:171-179.
35. Lei YX, Chen JK, Wu ZL: Blocking the translation elongation factor-1 delta with its antisense mRNA results in a significant reversal of its oncogenic potential. Teratog Carcinog Mutagen 2002, 22:377-383.
36. Opwa K, Utsunomiya T, Mimori K, Tanaka Y, Tanaka F, Inoue H, Murayama S, Mori M: Clinical significance of elongation factor-1 delta mRNA expression in oesophageal carcinoma. Br J Cancer 2004, 91:282-286.
37. Ruggero D, Pandolfi PP: Does the ribosome translate cancer? Nat Rev Cancer 2003, 3:179-192.